SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Korro Bio to End Novo Nordisk Research and License Collaboration

Korro Bio received notice that Novo Nordisk elected to terminate the research collaboration and license agreement for convenience, effective February 1, 2027. The agreement covered an exclusive worldwide license for a cardiometabolic target; Novo Nordisk did not nominate a second target.

KRRO

Related stories